drugset
drugset / Trial / NCT05718882

Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

NCT05718882 ↗

Terminated 5 enrolled RenJi Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in combination with Aurora kinase A inhibitor VIC-1911 in participate with lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(HCC).

Timeline

Start
2023-08-30
Primary completion
2024-04-02
Completion
2024-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral
Subject VIC-1911 Unknown 50 mg Oral
Subject VIC-1911 Unknown 100 mg Oral
Subject VIC-1911 Unknown 150 mg Oral
Subject VIC-1911 Unknown 200 mg Oral
Subject VIC-1911 Unknown 250 mg Oral

Indications

hepatocellular carcinoma refractory malignant neoplasm